Xu G - Search Results

1

Prognostic significance of CDC20 expression in malignancy patients: A meta-analysis.

Xian F, Yang X, Xu G. Xian F, et al. Among authors: xu g. Front Oncol. 2022 Nov 21;12:1017864. doi: 10.3389/fonc.2022.1017864. eCollection 2022. Front Oncol. 2022. PMID: 36479068 Free PMC article.

2

Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis.

Xian F, Wu C, Zhang G, Xu G. Xian F, et al. Among authors: xu g. Medicine (Baltimore). 2022 Nov 4;101(44):e31479. doi: 10.1097/MD.0000000000031479. Medicine (Baltimore). 2022. PMID: 36343054 Free PMC article.

3

Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Yang X, Deng H, Sun Y, Zhang Y, Lu Y, Xu G, Huang X. Yang X, et al. Among authors: xu g. J Hepatocell Carcinoma. 2023 Feb 27;10:303-313. doi: 10.2147/JHC.S399135. eCollection 2023. J Hepatocell Carcinoma. 2023. PMID: 36874252 Free PMC article.

4

Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis.

Xian F, Wu J, Zhong L, Xu G. Xian F, et al. Among authors: xu g. Medicine (Baltimore). 2023 Mar 10;102(10):e33204. doi: 10.1097/MD.0000000000033204. Medicine (Baltimore). 2023. PMID: 36897735 Free PMC article.

5

Automatic tumor segmentation and metachronous single-organ metastasis prediction of nasopharyngeal carcinoma patients based on multi-sequence magnetic resonance imaging.

Huang Y, Zhu Y, Yang Q, Luo Y, Zhang P, Yang X, Ren J, Ren Y, Lang J, Xu G. Huang Y, et al. Among authors: xu g. Front Oncol. 2023 Mar 28;13:953893. doi: 10.3389/fonc.2023.953893. eCollection 2023. Front Oncol. 2023. PMID: 37064158 Free PMC article.

6

Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.

Xian F, Ren D, Bie J, Xu G. Xian F, et al. Among authors: xu g. Front Immunol. 2023 Apr 17;14:1119168. doi: 10.3389/fimmu.2023.1119168. eCollection 2023. Front Immunol. 2023. PMID: 37138876 Free PMC article.

7

The potential role of CDC20 in tumorigenesis, cancer progression and therapy: A narrative review.

Xian F, Zhao C, Huang C, Bie J, Xu G. Xian F, et al. Among authors: xu g. Medicine (Baltimore). 2023 Sep 8;102(36):e35038. doi: 10.1097/MD.0000000000035038. Medicine (Baltimore). 2023. PMID: 37682144 Free PMC article. Review.

8

Silencing of peroxiredoxin 2 suppresses proliferation and Wnt/β-catenin pathway, and induces senescence in hepatocellular carcinoma.

Yang X, Xiang X, Xu G, Zhou S, An T, Huang Z. Yang X, et al. Among authors: xu g. Oncol Res. 2023 Nov 15;32(1):213-226. doi: 10.32604/or.2023.030768. eCollection 2023. Oncol Res. 2023. PMID: 38188679 Free PMC article.

9

Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Deng L, Sun Y, Wang H, Liao C, Li D, Xu G, Yang X. Deng L, et al. Among authors: xu g. J Hepatocell Carcinoma. 2024 Jan 9;11:29-38. doi: 10.2147/JHC.S443779. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 38223554 Free PMC article.

10

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).

Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW, Zhong BY, Sun JH, Jin ZC, Chen JJ, Ge NJ, Ding WB, Li WH, Huang JH, Mu W, Gu SZ, Li JP, Zhao H, Wen SW, Lei YM, Song YS, Yuan CW, Wang WD, Huang M, Zhao W, Wu JB, Wang S, Zhu X, Han JJ, Ren WX, Lu ZM, Xing WG, Fan Y, Lin HL, Zhang ZS, Xu GH, Hu WH, Tu Q, Su HY, Zheng CS, Chen Y, Zhao XY, Fang ZT, Wang Q, Zhao JW, Xu AB, Xu J, Wu QH, Niu HZ, Wang J, Dai F, Feng DP, Li QD, Shi RS, Li JR, Yang G, Shi HB, Ji JS, Liu YE, Cai Z, Yang P, Zhao Y, Zhu XL, Lu LG, Teng GJ; CHANCE001 Investigators. Zhu HD, et al. Among authors: xu gh, xu ab, xu j. Signal Transduct Target Ther. 2023 Feb 8;8(1):58. doi: 10.1038/s41392-022-01235-0. Signal Transduct Target Ther. 2023. PMID: 36750721 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16,073 results

Search Page